Cargando…

28665 Cutaneous T-cell lymphoma (CTCL) outcomes during COVID-19

Detalles Bibliográficos
Autores principales:	Garcia-Saleem, Tiffany J., Stonesifer, Connor J., Geskin, Larisa J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Mosby, Inc. 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349150/ http://dx.doi.org/10.1016/j.jaad.2021.06.827

Ejemplares similares

International Cutaneous Lymphomas Pandemic Section (ICLYPS) analysis of CTCL outcomes during COVID-19
por: Geskin, Larisa J, et al.
Publicado: (2021)

461 A review of cutaneous lymphoma outcomes during COVID-19 pandemic at Columbia University
por: Garcia-Saleem, T., et al.
Publicado: (2021)

Management of Mycosis Fungoides with Topical Chlormethine/Mechlorethamine Gel: A Columbia University Cutaneous Lymphoma Center Experience
por: GARCIA-SALEEM, Tiffany J., et al.
Publicado: (2021)

Stenotrophomonas maltophilia–associated primary cutaneous anaplastic large-cell lymphoma
por: Stonesifer, Connor J., et al.
Publicado: (2021)

Isolated cutaneous Pseudallescheria boydii abscess in an immunocompetent man
por: Stonesifer, Connor J., et al.
Publicado: (2022)

International Society for Cutaneous Lymphomas Pandemic Section (ICLYPS) analysis of cutaneous T-cell lymphoma outcomes during the COVID-19 pandemic: A retrospective cohort study
por: Geskin, Larisa J., et al.
Publicado: (2023)

Update on the treatment of cutaneous T-cell lymphoma (CTCL): Focus on vorinostat
por: Duvic, Madeleine, et al.
Publicado: (2007)

Cutaneous T-cell lymphoma (CTCL) exacerbation after viral vector COVID-19 vaccination
por: Panou, Evdoxia, et al.
Publicado: (2021)

The Ectopic Expression of Meiosis Regulatory Genes in Cutaneous T-Cell Lymphomas (CTCL)
por: Gantchev, Jennifer, et al.
Publicado: (2019)

The Skin Microbiome in Cutaneous T-Cell Lymphomas (CTCL)—A Narrative Review
por: Łyko, Magdalena, et al.
Publicado: (2022)

Maintenance and Concomitant Therapy Use with Chlormethine Gel Among Patients with Stage IA/IB Mycosis Fungoides-Type Cutaneous T-Cell Lymphoma (MF-CTCL): A Real-World Evidence Study
por: Querfeld, Christiane, et al.
Publicado: (2022)

JAK3 Is Expressed in the Nucleus of Malignant T Cells in Cutaneous T Cell Lymphoma (CTCL)
por: Vadivel, Chella Krishna, et al.
Publicado: (2021)

Safety and danger of biologic treatments in psoriasis in context of cutaneous T-cell lymphoma (CTCL)
por: Kołkowski, Karol, et al.
Publicado: (2021)

Environmental and Other Extrinsic Risk Factors Contributing to the Pathogenesis of Cutaneous T Cell Lymphoma (CTCL)
por: Ghazawi, Feras M., et al.
Publicado: (2019)

The mycosis fungoides cutaneous microenvironment shapes dysfunctional cell trafficking, antitumor immunity, matrix interactions, and angiogenesis
por: Gaydosik, Alyxzandria M., et al.
Publicado: (2023)

A study of meiomitosis and novel pathways of genomic instability in cutaneous T-cell lymphomas (CTCL)
por: Tsang, Matthew, et al.
Publicado: (2018)

Management of mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL): focus on chlormethine gel
por: Denis, Daphné, et al.
Publicado: (2019)

Harnessing the synergistic potential of biologically targeted therapies in cutaneous T-cell lymphoma
por: Patrone, Christina Chung, et al.
Publicado: (2019)

NRAS mutations in cutaneous T cell lymphoma (CTCL) sensitize tumors towards treatment with the multikinase inhibitor Sorafenib
por: KieΔling, Michael K., et al.
Publicado: (2017)

Pyoderma gangrenosum in a patient with cutaneous T-cell lymphoma
por: Tang, Randy, et al.
Publicado: (2015)

B-lymphoid tyrosine kinase (Blk) is an oncogene and a potential target for therapy with dasatinib in cutaneous T-cell lymphoma (CTCL)
por: Petersen, D L, et al.
Publicado: (2014)

Contemporary Treatment Patterns and Response in Relapsed/Refractory Cutaneous T-Cell Lymphoma (CTCL) across Five European Countries
por: Assaf, Chalid, et al.
Publicado: (2021)

United States Cutaneous Lymphoma Consortium recommendations for treatment of cutaneous lymphomas during the COVID-19 pandemic
por: Zic, John A., et al.
Publicado: (2020)

Synergistic cytotoxic activity of cannabinoids from cannabis sativa against cutaneous T-cell lymphoma (CTCL) in-vitro and ex-vivo
por: Mazuz, Moran, et al.
Publicado: (2020)

Connecting the dots in cutaneous T cell lymphoma (CTCL): STAT5 regulates malignant T cell proliferation via miR-155
por: Litvinov, Ivan V, et al.
Publicado: (2013)

Immune Checkpoint Inhibition in Non-Melanoma Skin Cancer: A Review of Current Evidence
por: Stonesifer, Connor J., et al.
Publicado: (2021)

Dysregulation of the TOX-RUNX3 pathway in cutaneous T-cell lymphoma
por: Dulmage, Brittany O., et al.
Publicado: (2019)

Mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL) epidemiology and treatment pathway in Spain: new insights for an accurate description
por: D’Agostino, Paolo, et al.
Publicado: (2020)

Simultaneous Inhibition of mTOR-Containing Complex 1 (mTORC1) and MNK Induces Apoptosis of Cutaneous T-Cell Lymphoma (CTCL) Cells
por: Marzec, Michal, et al.
Publicado: (2011)

Accessibility and readability of online patient education on cutaneous lymphomas
por: Schreidah, Celine M., et al.
Publicado: (2023)

Chlormethine Gel for the Treatment of Skin Lesions in All Stages of Mycosis Fungoides Cutaneous T-Cell Lymphoma: A Narrative Review and International Experience
por: Geskin, Larisa J., et al.
Publicado: (2021)

Mechlorethamine Hydrochloride Gel in the Treatment of Mycosis Fungoides–Type Cutaneous T-Cell Lymphoma (MF-CTCL): A Focus on Patient Selection and Special Considerations
por: Crimp, Caitlin, et al.
Publicado: (2022)

Ectopic expression of a novel CD22 splice-variant regulates survival and proliferation in malignant T cells from cutaneous T cell lymphoma (CTCL) patients
por: Bagdonaite, Ieva, et al.
Publicado: (2015)

Retraction: Simultaneous Inhibition of mTOR-Containing Complex 1 (mTORC1) and MNK Induces Apoptosis of Cutaneous T-Cell Lymphoma (CTCL) Cells
Publicado: (2020)

Targeting the non‐ATP‐binding pocket of the MAP kinase p38γ mediates a novel mechanism of cytotoxicity in cutaneous T‐cell lymphoma (CTCL)
por: Zhang, Xu Hannah, et al.
Publicado: (2021)

CCR4‐IL2 bispecific immunotoxin is more effective than brentuximab for targeted therapy of cutaneous T‐cell lymphoma in a mouse CTCL model
por: Wang, Zhaohui, et al.
Publicado: (2023)

Brentuximab vedotin: targeting CD30 as standard in CTCL
por: Prince, H. Miles, et al.
Publicado: (2018)

Assessment of clinical interruptions during the COVID-19 pandemic on the diagnosis of melanoma: A 30-month retrospective review
por: Stonesifer, Connor J., et al.
Publicado: (2022)

Lupus Erythematosus Tumidus Mimicking Primary Cutaneous Marginal Zone B-cell Lymphoma
por: TRAGER, Megan H., et al.
Publicado: (2020)

Concomitant Inhibition of FASN and SREBP Provides a Promising Therapy for CTCL
por: Chi, Cheng, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hi4v6kk2aqcaq48im9ehm56tn1